Forskning ved Københavns Universitet - Københavns Universitet

Forside

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  • Per Olov Hedlund
  • Martti Ala-Opas
  • Einar Brekkan
  • Jan Erik Damber
  • Lena Damber
  • Inger Hagerman
  • Svein Haukaas
  • Peter Henriksson
  • Peter Iversen
  • Ake Pousette
  • Finn Rasmussen
  • Jaakko Salo
  • Sigmund Vaage
  • Eberhard Varenhorst
  • Scandinavian Prostatic Cancer Group
In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects.
OriginalsprogEngelsk
TidsskriftScandinavian Journal of Urology and Nephrology
Vol/bind36
Udgave nummer6
Sider (fra-til)405-13
Antal sider9
ISSN0036-5599
DOI
StatusUdgivet - 1 jan. 2002

ID: 34081040